Free Trial

PepGen (PEPG) Competitors

PepGen logo
$4.50 -0.05 (-1.10%)
Closing price 04:00 PM Eastern
Extended Trading
$4.51 +0.01 (+0.31%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PEPG vs. CMPS, SVRA, MGTX, GLUE, SNDL, ZVRA, SIGA, RGNX, CMPX, and MLTX

Should you be buying PepGen stock or one of its competitors? The main competitors of PepGen include COMPASS Pathways (CMPS), Savara (SVRA), MeiraGTx (MGTX), Monte Rosa Therapeutics (GLUE), SNDL (SNDL), Zevra Therapeutics (ZVRA), Siga Technologies (SIGA), REGENXBIO (RGNX), Compass Therapeutics (CMPX), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

PepGen vs. Its Competitors

PepGen (NASDAQ:PEPG) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

PepGen presently has a consensus target price of $8.40, indicating a potential upside of 86.67%. COMPASS Pathways has a consensus target price of $16.00, indicating a potential upside of 156.41%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, analysts clearly believe COMPASS Pathways is more favorable than PepGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PepGen
2 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33
COMPASS Pathways
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

58.0% of PepGen shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 5.2% of PepGen shares are held by company insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

COMPASS Pathways' return on equity of -87.89% beat PepGen's return on equity.

Company Net Margins Return on Equity Return on Assets
PepGenN/A -92.51% -70.39%
COMPASS Pathways N/A -87.89%-57.77%

PepGen has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500.

In the previous week, COMPASS Pathways had 1 more articles in the media than PepGen. MarketBeat recorded 3 mentions for COMPASS Pathways and 2 mentions for PepGen. PepGen's average media sentiment score of 0.76 beat COMPASS Pathways' score of 0.24 indicating that PepGen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PepGen
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
COMPASS Pathways
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

COMPASS Pathways is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PepGenN/AN/A-$89.98M-$2.96-1.52
COMPASS PathwaysN/AN/A-$155.12M-$1.84-3.39

Summary

COMPASS Pathways beats PepGen on 8 of the 13 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PEPG vs. The Competition

MetricPepGenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$147.60M$3.42B$6.17B$10.67B
Dividend YieldN/A2.24%5.72%4.86%
P/E Ratio-1.5223.2129.5928.52
Price / SalesN/A477.49578.90129.07
Price / CashN/A45.5937.1261.42
Price / Book1.2410.3412.046.52
Net Income-$89.98M-$52.53M$3.32B$276.75M
7 Day Performance-6.25%-0.29%-0.17%0.21%
1 Month Performance130.77%10.83%5.75%1.68%
1 Year Performance-48.28%14.10%65.69%32.79%

PepGen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PEPG
PepGen
3.195 of 5 stars
$4.50
-1.1%
$8.40
+86.7%
-47.7%$147.60MN/A-1.5230
CMPS
COMPASS Pathways
2.7705 of 5 stars
$6.75
+3.5%
$16.00
+137.0%
-0.5%$625.54MN/A-3.67120Upcoming Earnings
SVRA
Savara
3.1003 of 5 stars
$4.11
+13.9%
$7.50
+82.5%
+18.8%$623.94MN/A-8.2220Trending News
Analyst Forecast
Gap Up
High Trading Volume
MGTX
MeiraGTx
4.3495 of 5 stars
$8.24
+6.3%
$24.00
+191.3%
+46.2%$623.47M$33.28M-4.04300News Coverage
Analyst Forecast
Insider Trade
GLUE
Monte Rosa Therapeutics
2.2563 of 5 stars
$9.87
-1.8%
$15.33
+55.4%
+76.1%$620.68M$177.99M27.4290News Coverage
SNDL
SNDL
3.0645 of 5 stars
$2.36
+1.3%
$4.50
+90.7%
+2.3%$612.27M$671.81M-8.742,516
ZVRA
Zevra Therapeutics
2.693 of 5 stars
$11.15
+3.1%
$24.00
+115.2%
+29.0%$606.54M$23.61M-53.1020Analyst Downgrade
SIGA
Siga Technologies
2.0057 of 5 stars
$8.48
+2.2%
N/A+24.2%$594.33M$138.72M7.5040
RGNX
REGENXBIO
4.3757 of 5 stars
$12.64
+7.8%
$28.38
+124.5%
+27.1%$592.53M$83.33M-3.67370
CMPX
Compass Therapeutics
2.2774 of 5 stars
$4.05
-4.9%
$13.10
+223.5%
+127.3%$589.08M$850K-9.0020
MLTX
MoonLake Immunotherapeutics
2.8976 of 5 stars
$9.35
+2.5%
$36.00
+285.0%
-80.0%$585.78MN/A-3.362Trending News

Related Companies and Tools


This page (NASDAQ:PEPG) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners